Innate Pharma SA
LSE:0EVI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Innate Pharma SA
LSE:0EVI
|
FR |
|
V
|
Veradermics Inc
NYSE:MANE
|
US |
|
Bravura Solutions Ltd
ASX:BVS
|
AU |
Wall St Price Targets
0EVI Price Targets Summary
Innate Pharma SA
According to Wall Street analysts, the average 1-year price target for 0EVI is 5.457 EUR with a low forecast of 4.545 EUR and a high forecast of 6.51 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 0EVI's stock price target?
Price Target
5.457
EUR
According to Wall Street analysts, the average 1-year price target for 0EVI is 5.457 EUR with a low forecast of 4.545 EUR and a high forecast of 6.51 EUR.
What is the Revenue forecast for Innate Pharma SA?
Projected CAGR
174%
Over the last 14 years, the compound annual growth rate for Revenue has been -7%. The projected CAGR for the next 3 years is 174%.
What is the Gross Profit forecast for Innate Pharma SA?
Projected CAGR
1 086%
The compound annual growth rate for Gross Profit over the next 3 years is 1 086%.
